Table 2. Distribution of allele and genotype frequency of XRCC1-Arg399Gln and XPD-Lys751Gln polymorphisms in glaucoma patients and healthy controls.
|
Gene |
Controls n (%) |
Patients n (%) |
OR (95% CI) |
p-value |
| XPD | ||||
| Lys/Lys |
25 (21) |
33 (23) |
Reference |
|
| Lys/Gln |
74 (61) |
87 (60) |
0.89 (0.46-1.70) |
0.82 |
| Gln/Gln |
22 (18) |
24 (17) |
0.82 (0.35-1.93) |
0.77 |
| A (Lys) allele frequency |
0.51 |
0.53 |
||
| C (Gln) allele frequency |
0.49 |
0.47 |
1.08 (0.60-1.96) |
0.88 |
| XRCC1 | ||||
| Arg/Arg |
34 (28) |
56 (40) |
Reference |
|
| Arg/Gln |
76 (63) |
78 (55) |
0.62 (0.35-1.10) |
0.11 |
| Gln/Gln |
11 (9) |
10 (5) |
0.55 (0.19-1.58) |
0.33 |
| G (Arg) allele frequency |
0.6 |
0.65 |
||
| A (Gln) allele frequency | 0.4 | 0.35 | 0.77 (0.41-1.43) | 0.46 |
A two-side χ2 test was used to compare the distribution of the genotypes and alleles between cases and controls. Conditional logistic regression analysis was performed to calculate the odds ratios (OR) with 95% confidence intervals (CI) for estimating the strength of the association between polymorphism genotype alleles and patients and controls. No statistically significant differences were observed in the alleles or in the genotype frequencies of the XRCC1-Arg399Gln and XPD-Lys751Gln gene polymorphisms between the control group and the patients with POAG.